Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

Hans Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry Arnason, Giancarlo Comi, Stuart Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, Karola Beckmann, Brigitte Stemper, Gustavo Suarez, Rupert Sandbrink, Christoph Pohl

Research output: Contribution to journalArticlepeer-review


Multiple sclerosis (MS) is a chronic demyelinating neurodegenerative disease of the CNS that requires long-term treatment. The identification of patient characteristics that can help predict disease outcomes could improve care for patients with MS. The objective of this study is to identify predictors of disease activity in patients from the BEYOND trial. This regression analysis of patients with relapsing–remitting MS from BEYOND examined the predictive value of patient characteristics at baseline and after 1 year of treatment with interferon beta-1b 250 μg every other day for clinical and MRI outcomes after year 1 of the study. 857 and 765 patients were included in the analyses of clinical and MRI outcomes, respectively. In multivariate analyses of age, a higher number of relapses in the past 2 years, ≥3 new MRI lesions in the first year, and, especially, a higher number of relapses in year 1 predicted the future occurrence of relapses. By contrast, age, MRI activity, and the presence of neutralizing antibodies in the first year were principally predictive of future MRI activity. In patients with continued clinical disease activity or substantial MRI activity on therapy, an alternative therapeutic approach should be strongly considered.

Original languageEnglish
JournalJournal of Neurology
Publication statusAccepted/In press - Aug 5 2015


  • Interferon beta-1b
  • MRI lesion
  • Multiple sclerosis
  • Predictor
  • Relapse

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Predictors of disease activity in 857 patients with MS treated with interferon beta-1b'. Together they form a unique fingerprint.

Cite this